期刊
CANCER RESEARCH
卷 78, 期 12, 页码 3147-3162出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-17-3006
关键词
-
类别
资金
- NIH [R01 CA157429, R01 CA192894, R01 CA196835, R01 CA196634]
- Purdue University Center for Cancer Research [P30 CA023168]
- NATIONAL CANCER INSTITUTE [R01CA192894, R01CA157429, R01CA196634, P30CA023168, R01CA196835] Funding Source: NIH RePORTER
Enzalutamide is a second-generation nonsteroidal antiandrogen clinically approved for the treatment of castration-resistant prostate cancer (CRPC), yet resistance to endocrine therapy has limited its success in this setting. Although the androgen receptor (AR) has been associated with therapy failure, the mechanisms underlying this failure have not been elucidated. Bioinformatics analysis predicted that activation of the Wnt/beta-catenin pathway and its interaction with AN play a major role in acquisition of enzalutamide resistance. To validate the finding, we show upregulation of beta-catenin and AR in enzalutamide-resistant cells, partially due to reduction of beta-TrCP-mediated ubiquitination. Although activation of the Wnt/beta-catenin pathway in enzaluta- mide-sensitive cells led to drug resistance, combination of beta-cateinn inhibitor ICG001 with enzalutamide inhibited expression of stem-like markers, cell proliferation, and tumor growth synergistically in various models. Analysis of clinical datasets revealed a molecule pattern shift in different stages of prostate cancer, where we detected a significant correlation between AR and beta-catenin expression. These data identify activation of the Wnt/beta-catenin pathway as a major mechanism contributing to enzalutamide resistance and demonstrate the potential to stratify patients with high risk of said resistance. Significance: Wnt/beta-catenin inhibition resensitizes prostate cancer cells to enzalutamide. (C) 2018 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据